Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q3 2026
Jazz Pharmaceuticals (JAZZ) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 2, 2026
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2B for the third quarter 2026 (Q3 2026), +10% from a year earlier and +3% from the quarter before. Operating margin was -33.3%, net loss $483M (38.9% of revenue).
Jazz Pharmaceuticals, Q3 2026: revenue $1.2B (+10% year over year), operating margin -33.3%, net loss $483M, operating cash flow $506M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2B | +3% | +10% |
| Operating profit | −$413M | -267% | -819% |
| Net earnings | −$483M | -351% | -292% |
| Operating cash flow | $506M | +22% | +7% |
| Free cash flow | $490M | +23% | +7% |
What changed
Revenue was $1.2B in Q3 2026, up 10% year over year and up 3% from the previous quarter. Sleep was the largest line at 41% of revenue. Modeyso added $0.05B year over year (up 455%), 43% of the total change. High-sodium oxybate AG royalty revenue declined 27%.
Operating costs exceeded revenue by $0.41B, an operating margin of -33.3%. Total costs grew 55% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+205%). The quarter ended with a net loss of $0.48B, after a profit of $0.19B the previous quarter.
Operating cash flow was $0.51B (up 7% year over year). Non-cash charges added back $0.18B of depreciation and amortization and $0.08B of share-based compensation. Working capital and other items added $0.73B. Capital expenditures of $0.02B left free cash flow of $0.49B.
Questions
What was Jazz Pharmaceuticals' revenue in the third quarter 2026?
Jazz Pharmaceuticals (JAZZ) reported revenue of $1.2B for the third quarter 2026 (Q3 2026), +10% from a year earlier and +3% from the quarter before.
Was Jazz Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $413M (-33.3% of revenue) and net loss $483M.